At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
PHAT Phathom Pharmaceuticals
Not Yet Opened 12-20 16:00:00 EST
7.45
-0.37
-4.73%
盘后7.45
+0.000.00%
19:03 EST
High7.83
Low7.39
Vol2.48M
Open7.71
D1 Closing7.82
Amplitude5.63%
Mkt Cap509.41M
Tradable Cap415.34M
Total Shares68.38M
T/O18.63M
T/O Rate4.44%
Tradable Shares55.75M
P/B--
ROE--
EPS0.00
52wk High--
52wk Low--
P/E--
Dividend--
Div.Yield--
ROA--
Insider Sellers Might Regret Selling Phathom Pharmaceuticals Shares at a Lower Price Than Current Market Value
Phathom Pharmaceuticals, Inc., biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada for an investigational potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection. Phathom Pharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Florham Park, New Jersey.